Thymosin Alpha-1 vs LL-37
A comparison of Thymosin Alpha-1 and LL-37 as immune-modulating peptides, including mechanism, immune system targets, clinical context, and research applications.
A comparison of Thymosin Alpha-1 and LL-37 as immune-modulating peptides, including mechanism, immune system targets, clinical context, and research applications.
Overview
Thymosin Alpha-1 and LL-37 are both studied in immune modulation research, but they act through very different mechanisms and address different aspects of immune function. Thymosin Alpha-1 is primarily discussed in the context of T-cell maturation and adaptive immune enhancement, while LL-37 is studied more as an innate immune defense peptide with antimicrobial and immunoregulatory properties.
Mechanism Comparison
Thymosin Alpha-1 is a naturally occurring thymic peptide studied for enhancing T-cell function, regulatory T-cell modulation, and broad immune system support. It has been used clinically in hepatitis and cancer immunotherapy contexts. LL-37 is a cathelicidin antimicrobial peptide studied for direct antimicrobial activity, wound-healing support, and modulation of toll-like receptor signaling in innate immunity.
Dosing and Protocol Comparison
Thymosin Alpha-1 has published clinical protocols primarily via subcutaneous injection, with dosing in the 1–1.6 mg range in clinical research. LL-37 research spans both injectable and topical routes depending on the target tissue, and dosing is less standardized given the compound's role varies from antimicrobial to immunoregulatory depending on the study design.
Evidence Comparison
Thymosin Alpha-1 has a more extensive published human evidence base, including clinical trials in hepatitis, cancer, and sepsis. LL-37 has a strong preclinical evidence base for antimicrobial and wound-healing applications, but more limited human clinical research. The compounds are best compared not as substitutes but as representatives of different immune intervention strategies: adaptive vs. innate.